Replies to post #56813 on Amarin Corp Plc (AMRN)

[marzan]

ok guys lets move on; whatever hell the FDA do with the exclusivity, let them do taking any amount of time, but one thing is sure: generics can't get in now. That's what we wanted and we got it. Otherwise remember the NPE expired in July. So we are in good shape, lets forget about this exclusivity and lets go with the market as it plays out! With 1A marketing already started, we should see increase in scripts exponentially. Also I hope the management might announce some partnership shortly.

[HDGabor]

BB-

Thanks.

Essentially, Vascepa will never gain the benefits of exclusivity.

Some thoughts:
- V / and AMRN has (will have) all operational benefits from exclusivity: no ANDA till 2020
- maybe (or sure) shareholders have a feeling that they lost something (no BO in 2012 @ $20), but the chance is very good, that it was not a loss, the return could be nice (I mean: $20 in 2012 vs. $30+ (or +/-$50) in 2016) if R-IT will be stopped at interim

It (pps does not affect daily operation) is true for a lot of things.

Best,
G